Drew Angerer/Getty Images News ARS Pharmaceuticals ( NASDAQ: SPRY ) has launched neffy , an epinephrine nasal spray, in the U.S. market.
The drug won U.S. FDA approval in August for anaphylaxis in individuals who weigh at least 66 pounds.
EURneffy (adrenaline nasal spray), which also won approval in the.
